Search
Tivic Health Systems Inc
TIVCAdd to Watchlist
1.400USD
0.0000.00%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
1.76MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
0.00%
5 Days
0.00%
1 Month
0.00%
6 Months
-10.83%
Year to Date
-3.45%
1 Year
-63.21%
Key Figures
--Open
0.000High
0.00Volume
LossP/E TTM
--P/E Dynamic
--Dividend TTM
21.80%Turnover Ratio
1.400Prev. Close
0.000Low
0.00Turnover
LossP/E Static
0.42P/B
0.00%Div Yield TTM
-46.45%ROA
7.55052wk High
0.73Volume Ratio
-5.66MNet Profit
1.66MShares
-7.8371EPS TTM
2.18Beta
-84.53%ROE
0.72252wk Low
12.78%Amplitude
-13.58%Gross Margin
1.76MMarket Cap
7.40Reward/Risk
5.82%Risk Rate
TradingKey Stock Score of Tivic Health Systems Inc
Currency: USD Updated: 2026-04-27Key Insights
Tivic Health Systems Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 146 out of 208 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Tivic Health Systems Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Tivic Health Systems Inc Highlights
StrengthsRisks
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Undervalued
The company’s latest PE is -0.18, at a low 3-year percentile range.
Institutional Buying
The latest institutional holdings are 240.28K shares, increasing 30.47% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 0.00 shares of this stock.
Analyst Rating
Based on
0
analysts
--
Current Rating
--
Target Price
--
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Tivic Health Systems Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Tivic Health Systems Inc Info
Tivic Health Systems, Inc. is a diversified therapeutics company, with complementary bioelectronic and biologic product candidates in its clinical pipeline. It harnesses the power of the immune and autonomic nervous systems to fight disease and restore health. It takes a multi-pronged approach to treating diseases caused by immune dysregulation and dysautonomia. The complement of bioelectronic and biologic medicines allows it to target disorders and disease via both neural pathways and molecular approaches. Its commercial product, ClearUP, is clinically proven to treat sinus pain and pressure. ClearUP is available through online retailers and commercial distributors. It also has worldwide exclusive license rights to the late-stage Toll-like Receptor 5 (TLR5) agonist Entolimod for the treatment of acute radiation syndrome (ARS). In addition, it has an exclusive option to license five additional indications and clinical use cases for Entolimod and its derivative, Entalasta.
Ticker SymbolTIVC
CompanyTivic Health Systems Inc
CEOErnst (Jennifer)
Websitehttps://tivichealth.com/
Related Instruments
-1.10%
-1.12%
-2.20%
-2.04%
-1.28%
-0.15%
-4.84%
-3.35%
-0.64%
-0.36%
-1.11%
-1.86%
+0.49%
-0.86%
+2.15%
-1.77%
-2.57%
-0.32%
-0.03%
-0.43%Popular Instruments
FAQs
What is the current price of Tivic Health Systems Inc (TIVC)?
The current price of Tivic Health Systems Inc (TIVC) is 1.40.
What is the symbol of Tivic Health Systems Inc?
The ticker symbol of Tivic Health Systems Inc is TIVC.
What is the 52-week high of Tivic Health Systems Inc?
The 52-week high of Tivic Health Systems Inc is 7.55.
What is the 52-week low of Tivic Health Systems Inc?
The 52-week low of Tivic Health Systems Inc is 0.72.
What is the market capitalization of Tivic Health Systems Inc?
The market capitalization of Tivic Health Systems Inc is 1.76M.
What is the Earnings Per Share (EPS TTM) of Tivic Health Systems Inc (TIVC)?
The Earnings Per Share (EPS TTM) of Tivic Health Systems Inc (TIVC) is -7.84.
